5 May 2016 13:30
For immediate release | 5 May 2016 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Director Shareholding
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was notified on 4 May 2016 that on 3 May 2016 David Cook, a Non-Executive Director of the Company, purchased 54,492 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 46.54 pence per share, and his spouse, Katharine Cook, also purchased 47,879 Ordinary Shares on the same date at 46.52 pence per share.
Following this transaction, Mr Cook's total beneficial interest in the Company is 102,371 Ordinary Shares, representing approximately 0.02% of the Company's issued share capital.
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer | |
Sarah Robinson, Company Secretary | |
www.alliancepharma.co.uk | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Sophie Cowles / Jane Glover | |
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Freddie Barnfield | |
Corporate Broking: James Black / Toby Adcock |
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Alliance Pharma (APH)